Sugi Predict

Sugi Predict / Compounds / SCHEMBL9900293

SCHEMBL9900293

SCHEMBL9900293

CC1CCOc2cccc(Oc3ncc([N+](=O)[O-])cn3)c21

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ MAP3K14 Q99558 1/20 0.33
▸ MEN1 O00255 3/20 0.32
▸ KMT2A Q03164 3/20 0.32
▸ ACHE P22303 2/20 0.32
▸ PKM P14618 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.31
▸ PAX8 Q06710 1/20 0.31
▸ KLF5 Q13887 1/20 0.31
▸ HSPB1 P04792 2/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ ALDH1A1 P00352 2/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ PABPC1 P11940 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9900943 0.87 HSPB1 (0.46) MAPTMAPK1MEN1KMT2APKM
SCHEMBL9905713 0.82 MAP3K14 (0.37) MAP3K14
SCHEMBL19400272 0.79 ALDH1A1 (0.39) MAPTMAPK1MAP3K14KMT2AALDH1A1
SCHEMBL15303377 0.75 MAPT (0.36) MAPTMAPK1MEN1KMT2APKM
SCHEMBL9901409 0.74 MAPT (0.39) MAPTMAPK1MEN1KMT2APKM
SCHEMBL9900568 0.73 HTR1A (0.32) —
SCHEMBL30939525 0.73 HTR1A (0.32) —
SCHEMBL15303513 0.72 MTNR1A (0.35) MAPK1MAP3K14RAB9A
SCHEMBL15303511 0.72 MTNR1A (0.35) MAPK1MAP3K14RAB9A
SCHEMBL21116386 0.72 MTNR1A (0.35) MAPK1MAP3K14RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 — — US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 — — US disclosed
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUCTICS LIMITED (GB) 2019-04-23 — — US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 — — US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 — — US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 — — US disclosed
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 — — US disclosed
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 — — US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 — — US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 — — US disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 — — EP disclosed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 — — EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MAPT 3926/4885MAPK1 2419/4885MAP3K14 1541/4885
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 MAPT 3971/4885MAPK1 2156/4885MAP3K14 1283/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 MAPT 3926/4885MAPK1 2419/4885MAP3K14 1541/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MAPT 3926/4885MAPK1 2419/4885MAP3K14 1541/4885
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 MAPT 3926/4885MAPK1 2419/4885MAP3K14 1541/4885
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 MAPT 3971/4885MAPK1 2156/4885MAP3K14 1283/4885
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNA3, KCND3, KCNN3 MAPT 3971/4885MAPK1 2156/4885MAP3K14 1283/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 MAPT 3971/4885MAPK1 2156/4885MAP3K14 1283/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 MAPT 3926/4885MAPK1 2419/4885MAP3K14 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.